Authors
Orsola Crespi, Umberto Santaniello, François Rosset, Valentina Pala, Simone Ribero, Pietro Quaglino
Published in
Italian journal of dermatology and venereology. Volume 161. Issue 5. Pages 487-496.
Abstract
Immune checkpoint inhibitors (ICIs) and targeted therapies have transformed the management of advanced malignancies but are associated with characteristic adverse events (AEs), many of which are skin-predominant. Increasing evidence indicates that selected treatment-related AEs, particularly immune-related adverse events (irAEs) and on-target toxicities, may serve as dynamic biomarkers of antitumor activity. This review summarizes current data on the incidence, spectrum, and prognostic significance of irAEs and targeted-therapy AEs, with a specific emphasis on cutaneous events relevant to dermatologists. We highlight the robust association between cutaneous irAEs (cirAEs) - including vitiligo, regression of melanocytic nevi and halo phenomena in melanoma - and improved clinical outcomes. We also examine prognostic data for other cutaneous patterns (lichenoid, psoriasiform, bullous), endocrine and other organ-specific irAEs, and on-target dermatologic toxicities under epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR), and BRAF/MEK inhibition. Finally, we discuss mechanistic hypotheses and practical implications for dermatology practice, stressing the need to balance recognition of toxicity as a favorable biomarker with timely management to avoid treatment interruption.
PMID:
43043303
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0